OnKure Therapeutics, Inc.
$ 4.19
-2.56%
05 Jun - close price
- Market Cap 169,257,000 USD
- Current Price $ 4.19
- High / Low $ 4.42 / 4.14
- Stock P/E N/A
- Book Value 4.56
- EPS -4.32
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.26 %
- ROE -0.43 %
- 52 Week High 5.38
- 52 Week Low 1.91
About
OnKure, Inc. engages in the discovery and development of oncology-precision medicines for the treatment of cancer. The company is headquartered in Boulder, Colorado.
Analyst Target Price
$20.20
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-05 | 2026-03-12 | 2025-11-06 | 2025-08-12 | 2025-05-06 | 2025-03-10 | 2024-11-07 | 2024-08-13 | 2024-05-07 | 2024-03-28 | 2023-11-13 | 2023-08-10 |
| Reported EPS | -1.11 | -0.99 | -1.09 | -1.14 | -1.1863 | -1.37 | -0.86 | -1.6041 | -2.5212 | -7.0477 | -5.678 | -6.4639 |
| Estimated EPS | -0.7425 | -1.152 | -1.198 | -1.248 | -1.38 | -0.87 | -0.9 | None | None | None | None | None |
| Surprise | -0.3675 | 0.162 | 0.108 | 0.108 | 0.1937 | -0.5 | 0.04 | 0 | 0 | 0 | 0 | 0 |
| Surprise Percentage | -49.4949% | 14.0625% | 9.015% | 8.6538% | 14.0362% | -57.4713% | 4.4444% | None% | None% | None% | None% | None% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: OKUR
2026-04-24 20:10:00
OnKure Therapeutics (NASDAQ: OKUR) has filed an S-3 shelf registration statement to allow selling shareholders to resell up to 36.1 million shares of Class A common stock. This includes 26.7 million existing shares and 9.4 million shares issuable upon the exercise of pre-funded warrants. The company will not receive proceeds from these resales, unless pre-funded warrants are exercised for cash.
2026-03-03 02:52:38
OnKure Therapeutics has completed its merger with Reneo Pharmaceuticals and a concurrent $65 million private placement, with the combined company now trading on Nasdaq as OKUR. This transaction provides OnKure with approximately $139 million in cash, extending its operational runway into Q4-2026, and is focused on advancing its lead program, OKI-219, for PI3KαH1047R mutations in breast cancer with early clinical data expected in Q4-2024. Nicholas A. Saccomano, Ph.D., will lead the new entity as President and CEO.
2025-05-06 00:08:36
OnKure Therapeutics (NASDAQ: OKUR) is a clinical-stage biopharmaceutical company focused on precision medicines for cancers driven by PI3Kα mutations, with its lead candidate OKI-219 in Phase 1 clinical trials for advanced solid tumors. The company is also developing a broader PI3Kα-focused pipeline and exploring applications in vascular malformations. OKUR's recent financial highlights include a market cap of $54.4 million, trailing twelve-month net income of -$59.5 million, and a current ratio indicating strong liquidity.
2024-10-11 09:28:37
Cormorant Asset Management has strategically acquired 189,571.7 shares of Reneo Pharmaceuticals Inc. at $18.2 per share, marking a new holding and a 14.98% stake in the company. This investment, by the Boston-based firm known for its focus on healthcare and biotechnology, diversifies its portfolio within the sector. Reneo Pharmaceuticals, a clinical-stage company developing treatments for rare genetic mitochondrial diseases, faces financial challenges despite its innovative approach.
2024-10-07 09:09:21
OKUR Pharmaceuticals Inc. shares have reached an all-time high of $20, reflecting strong market confidence and investor optimism despite broader market volatility. This achievement, contrasted with the struggles of Reneo Pharmaceuticals, highlights the varied fortunes within the pharmaceutical sector. While OKUR shows strong short-term performance, InvestingPro insights indicate it is burning cash rapidly and is not profitable over the last year.
2024-10-07 07:31:36
OnKure and Reneo Pharmaceuticals have successfully completed their merger, with the combined company now operating as OnKure Therapeutics. The new entity's shares will trade on Nasdaq under the ticker "OKUR" following an all-stock deal and a $65 million private placement. The merger aims to accelerate the development of OnKure's mutant-specific PI3Kα inhibitor portfolio, extending its cash runway through Q4 2026 for multiple clinical readouts.
